Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 6 Results

Title
Intervention Indication Therapeutic Area Year Actions
Brentuximab vedotin (Adcetris) for treatment naive Hodgkin’s Lymphoma Adriamycin , Brentuximab vedotin (Adcetris; SGN-35) , Dacarbazine (dacarbazine citrate) , Vinblastine (vinblastine sulfate) Hodgkin lymphoma Haematological Cancer and Lymphomas 2017 View  |  Download
Brentuximab vedotin with chemotherapy (BrECADD) for previously untreated advanced classical Hodgkin lymphoma Brentuximab vedotin (Adcetris; SGN-35) , Chemotherapy Hodgkin lymphoma Haematological Cancer and Lymphomas 2024 View  |  Download
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma Brentuximab vedotin (Adcetris; SGN-35) , Dacarbazine (dacarbazine citrate) , Doxorubicin (Livatag; BA-003; Caelyx; Sarcodoxome; SP-1049C; Resmycin; JNS002; doxorubicin hydrochloride) , Vinblastine (vinblastine sulfate) Hodgkin lymphoma Haematological Cancer and Lymphomas 2023 View  |  Download
Favezelimab-Pembrolizumab for treating relapsed or refractory classical Hodgkin Lymphoma after 2 or more therapies Favezelimab-pembrolizumab Hodgkin lymphoma Haematological Cancer and Lymphomas 2023 View  |  Download
Pembrolizumab (Keytruda) for relapsed/refractory classical Hodgkin lymphoma Pembrolizumab (Keytruda; MK-3475) Hodgkin lymphoma Haematological Cancer and Lymphomas 2018 View  |  Download
Phelinun for reduced intensity conditioning treatment prior to allogeneic haematopoietic stem cell transplantation Melphalan hydrochloride (Cydex; CDX-353; Phelinun) Acute myeloid leukaemia (AML) , Hodgkin lymphoma , Multiple myeloma (MM) , Neuroblastoma , Non-Hodgkin lymphoma (NHL) , Ovarian cancer Female Reproductive Cancer , Haematological Cancer and Lymphomas , Neurological Cancer 2021 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications